TY - JOUR
T1 - Evidence for intensive LDL-C lowering for acute coronary syndrome
T2 - Recommendations from the Lipid Association of India
AU - Puri, Raman
AU - Mehta, Vimal
AU - Duell, P. Barton
AU - Iyengar, S. S.
AU - Yusuf, Jamal
AU - Dalal, Jamshad
AU - Narasingan, S. N.
AU - Kalra, Dinesh
AU - Kapoor, Aditya
AU - Pradhan, Akshaya
AU - Mukhopadhyay, Saibal
AU - Vijayaraghavan, Krishnaswami
AU - Aggarwal, Rajeev
AU - Muruganathan, A.
AU - Prabhakar, D.
AU - Misra, Sundeep
AU - Shetty, Sadanand
AU - Kasliwal, Ravi R.
AU - Bansal, Manish
AU - Khanna, N.
AU - Khan, Aziz
AU - Melinkeri, Rashida Patanwala
AU - Kumar, Soumitra
AU - Chakraborty, Rabindra Nath
AU - Bardoloi, Neil
AU - Sahoo, Prasant
AU - Vinayagam, Palaniappen
AU - Modi, Ranjan
AU - Nanda, Rashmi
AU - Wong, Nathan D.
N1 - Publisher Copyright:
© 2022
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Patients with acute coronary syndrome (ACS) have a high risk of subsequent adverse cardiovascular outcomes, particularly within the first 30 days. Although it is well documented that initiation of statin therapy in the setting of ACS improves short- and long-term cardiovascular outcomes, and achievement of lower levels of low density lipoprotein cholesterol (LDL-C) incrementally improves outcomes, many patients with ACS have persistent hypercholesterolemia after discharge from the hospital. This is a missed opportunity that prompted the Lipid Association of India to develop recommendations for earlier initiation of more aggressive LDL-C lowering treatment, particularly for patients of South Asian descent who are well-documented to have earlier onset of more aggressive atherosclerotic cardiovascular disease. The Lipid Association of India recommends individualized aggressive LDL-C goals after ACS, which can be rapidly achieved with high intensity statin therapy and subsequent goal-directed adjunctive treatment with ezetimibe and PCSK9 inhibitors. Improved treatment of hypercholesterolemia achieved within weeks after ACS has the potential to reduce the high rate of morbidity and mortality in these high risk patients.
AB - Patients with acute coronary syndrome (ACS) have a high risk of subsequent adverse cardiovascular outcomes, particularly within the first 30 days. Although it is well documented that initiation of statin therapy in the setting of ACS improves short- and long-term cardiovascular outcomes, and achievement of lower levels of low density lipoprotein cholesterol (LDL-C) incrementally improves outcomes, many patients with ACS have persistent hypercholesterolemia after discharge from the hospital. This is a missed opportunity that prompted the Lipid Association of India to develop recommendations for earlier initiation of more aggressive LDL-C lowering treatment, particularly for patients of South Asian descent who are well-documented to have earlier onset of more aggressive atherosclerotic cardiovascular disease. The Lipid Association of India recommends individualized aggressive LDL-C goals after ACS, which can be rapidly achieved with high intensity statin therapy and subsequent goal-directed adjunctive treatment with ezetimibe and PCSK9 inhibitors. Improved treatment of hypercholesterolemia achieved within weeks after ACS has the potential to reduce the high rate of morbidity and mortality in these high risk patients.
KW - Acute coronary syndrome
KW - Alirocumab
KW - Evolocumab
KW - Ezetimibe
KW - Lipoprotein(a)
KW - Low density lipoprotein cholesterol (LDL-C)
KW - PCSK9
KW - Recommendations
KW - Statins
UR - http://www.scopus.com/inward/record.url?scp=85129978070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129978070&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2022.03.008
DO - 10.1016/j.jacl.2022.03.008
M3 - Article
C2 - 35508456
AN - SCOPUS:85129978070
SN - 1933-2874
VL - 16
SP - 261
EP - 271
JO - Journal of clinical lipidology
JF - Journal of clinical lipidology
IS - 3
ER -